αααααβααΎαDBVT β’ NASDAQ
add
DBV Technologies SA - ADR
20.59$
ααΆαβαααβααΌαβαα»αβααΈααααΆαα(2.14%)-0.44
20.15$
ααΆααα·αα 13 ααααΆ, 5:02:22 AM ααααβααα -4 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·α
αα·αααΈαα»α
21.40$
α
αααααααααααα
20.35$ - 21.24$
α
ααααααα½αααααΆαα
α»αααααα
6.83$ - 26.19$
ααΎαβαα»αβααΈααααΆα
1.12Β αααΈααΆα USD
ααα ααα½αααΌαααααα
274.09Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 645.00Β ααΆαα | 26.22% |
α
αααΆαααααα·ααααα·ααΆα | 45.70Β ααΆα | 87.49% |
α
αααΌααα»ααα | -44.83Β ααΆα | -94.78% |
ααααΆααα
αααααα»ααα | -6.95ααΆαα | -54.32% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | β | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -44.36Β ααΆα | -91.02% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -0.84% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 194.17Β ααΆα | 498.25% |
ααααααααα»α | 233.72Β ααΆα | 255.96% |
ααΆαααα½ααα»αααααΌαααα»α | 64.95Β ααΆα | 69.71% |
ααΌαβααααα»α | 168.77Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 235.60Β ααΆα | β |
ααααααααααΉαααααα
| 29.72 | β |
ααα
ααααααΎαααααα | -65.44% | β |
ααα
ααααααΎααΎααα»α | -95.51% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -44.83Β ααΆα | -94.78% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -35.17Β ααΆα | -187.08% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -715.00Β ααΆαα | -190.16% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 159.06Β ααΆα | 23,464.44% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 124.33Β ααΆα | 988.96% |
ααα αΌαααΆα
αααααΆααααααα | -17.23Β ααΆα | -302.81% |
α’αααΈ
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
ααΆααααααΎαα‘αΎα
29 ααΈααΆ 2002
αααααβαααααΆα
αα»ααααα·α
125
